Suppr超能文献

变应原并非病原体:为何过敏免疫不同于传染病疫苗接种。

Allergens are not pathogens: why immunization against allergy differs from vaccination against infectious diseases.

作者信息

Weiss Richard, Scheiblhofer Sandra, Thalhamer Josef

机构信息

Department of Molecular Biology; University of Salzburg; Salzburg, Austria.

出版信息

Hum Vaccin Immunother. 2014;10(3):703-7. doi: 10.4161/hv.27183. Epub 2013 Nov 26.

Abstract

Vaccination against infectious diseases has been one of the major breakthroughs in human medical history, saving the lives of millions of people each year. More recently, prophylactic vaccination against non-infectious diseases such as cancer, Alzheimer's disease, diabetes, and type I allergy is being investigated. Particularly in case of IgE-driven allergic disorders, which afflict almost a quarter of the population in highly developed countries, preventative measures would represent a major improvement for patients' health as well as an economic relief for public health services. As an alternative to allergen-specific immunotherapy, prophylactic vaccination against type I allergic diseases could slow down or even stop the progress of the allergy pandemic. Allergen-encoding gene-based vaccines, i.e., plasmid DNA and mRNA vaccines, provide the advantage of purity over crude allergen extracts, which involve the risk of de novo sensitizations. Furthermore, these formulations have been demonstrated to induce T helper 1 as well as T regulatory immune responses--a pre-requisite for prophylactic intervention against allergies. However, prophylactic vaccines against environmental allergens strikingly differ from conventional vaccines against infectious diseases or therapeutic approaches concerning the underlying immunological mechanisms.

摘要

针对传染病的疫苗接种一直是人类医学史上的重大突破之一,每年挽救数百万人的生命。最近,人们正在研究针对癌症、阿尔茨海默病、糖尿病和I型过敏等非传染性疾病的预防性疫苗接种。特别是在由IgE驱动的过敏性疾病方面,在高度发达国家几乎影响四分之一的人口,预防措施将对患者健康有重大改善,同时也为公共卫生服务减轻经济负担。作为变应原特异性免疫疗法的替代方法,针对I型过敏性疾病的预防性疫苗接种可以减缓甚至阻止过敏大流行的进程。基于变应原编码基因的疫苗,即质粒DNA疫苗和mRNA疫苗,比粗制变应原提取物具有纯度优势,粗制变应原提取物存在引发新致敏的风险。此外,这些制剂已被证明可诱导辅助性T细胞1以及调节性T细胞免疫反应,这是针对过敏进行预防性干预的先决条件。然而,针对环境变应原的预防性疫苗与针对传染病的传统疫苗或治疗方法在潜在免疫机制方面存在显著差异。

相似文献

2
DNA and mRNA vaccination against allergies.DNA 和 mRNA 疫苗接种防治过敏。
Pediatr Allergy Immunol. 2018 Nov;29(7):679-688. doi: 10.1111/pai.12964. Epub 2018 Sep 20.

引用本文的文献

4
DNA and mRNA vaccination against allergies.DNA 和 mRNA 疫苗接种防治过敏。
Pediatr Allergy Immunol. 2018 Nov;29(7):679-688. doi: 10.1111/pai.12964. Epub 2018 Sep 20.
9
The dichotomy of pathogens and allergens in vaccination approaches.疫苗接种方法中病原体和过敏原的二分法。
Front Microbiol. 2014 Jul 16;5:365. doi: 10.3389/fmicb.2014.00365. eCollection 2014.

本文引用的文献

2
RNA: the new revolution in nucleic acid vaccines.RNA:核酸疫苗的新革命。
Semin Immunol. 2013 Apr;25(2):152-9. doi: 10.1016/j.smim.2013.05.001. Epub 2013 Jun 2.
10
The hygiene hypothesis in allergy and asthma: an update.过敏和哮喘中的卫生假说:更新。
Curr Opin Allergy Clin Immunol. 2013 Feb;13(1):70-7. doi: 10.1097/ACI.0b013e32835ad0d2.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验